Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Jansen

Showing results (231-240 of 254) with videos related to

Pageof 26
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 21, 2026
Safety and Immunogenicity of a Fourth Dose of Omicron-BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18‒55 Years OldPatricia Winokur, Oyeniyi Diya, David Fitz-Patrick, et al.
The New England Journal of Medicine|July 19, 2023
Potential for Maternally Administered Vaccine for Infant Group B StreptococcusShabir A Madhi, Annaliesa S Anderson, Judith Absalon, et al.
Mbio|March 15, 2018
Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic VaccineLisa K McNeil, Robert G K Donald, Alexey Gribenko, et al.
The New England Journal of Medicine|May 27, 2021
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in AdolescentsRobert W Frenck, Nicola P Klein, Nicholas Kitchin, et al.
The Journal of Infection|February 25, 2015
Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategyCatherine A Jeppesen, Matthew D Snape, Hannah Robinson, et al.
The New England Journal of Medicine|December 10, 2020
Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineFernando P Polack, Stephen J Thomas, Nicholas Kitchin, et al.
The Journal of Infectious Diseases|June 19, 2009
Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidisEllen Murphy, Lubomira Andrew, Kwok-Leung Lee, et al.
The New England Journal of Medicine|January 18, 2023
Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 YearsPatricia Winokur, Juleen Gayed, David Fitz-Patrick, et al.
The New England Journal of Medicine|October 16, 2024
RENOIR Trial - RSVpreF Vaccine Efficacy over Two SeasonsEdward E Walsh, Gonzalo Pérez Marc, Ann R Falsey, et al.
The New England Journal of Medicine|September 15, 2021
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 MonthsStephen J Thomas, Edson D Moreira, Nicholas Kitchin, et al.
Pageof 26

Showing results (231-240 of 254) with videos related to

Sort By:
Pageof 26
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 21, 2026
Safety and Immunogenicity of a Fourth Dose of Omicron-BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18‒55 Years OldPatricia Winokur, Oyeniyi Diya, David Fitz-Patrick, et al.
The New England Journal of Medicine|July 19, 2023
Potential for Maternally Administered Vaccine for Infant Group B StreptococcusShabir A Madhi, Annaliesa S Anderson, Judith Absalon, et al.
Mbio|March 15, 2018
Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic VaccineLisa K McNeil, Robert G K Donald, Alexey Gribenko, et al.
The New England Journal of Medicine|May 27, 2021
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in AdolescentsRobert W Frenck, Nicola P Klein, Nicholas Kitchin, et al.
The Journal of Infection|February 25, 2015
Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategyCatherine A Jeppesen, Matthew D Snape, Hannah Robinson, et al.
The New England Journal of Medicine|December 10, 2020
Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineFernando P Polack, Stephen J Thomas, Nicholas Kitchin, et al.
The Journal of Infectious Diseases|June 19, 2009
Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidisEllen Murphy, Lubomira Andrew, Kwok-Leung Lee, et al.
The New England Journal of Medicine|January 18, 2023
Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 YearsPatricia Winokur, Juleen Gayed, David Fitz-Patrick, et al.
The New England Journal of Medicine|October 16, 2024
RENOIR Trial - RSVpreF Vaccine Efficacy over Two SeasonsEdward E Walsh, Gonzalo Pérez Marc, Ann R Falsey, et al.
The New England Journal of Medicine|September 15, 2021
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 MonthsStephen J Thomas, Edson D Moreira, Nicholas Kitchin, et al.
Pageof 26